Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07URD
|
|||
| Former ID |
DIB004804
|
|||
| Drug Name |
Pegunigalsidase alfa
|
|||
| Synonyms |
PRX-102; Galactosidase enzyme replacement therapy (Fabry disease), Protalix
Click to Show/Hide
|
|||
| Indication | Fabry disease [ICD-11: 5C56.01; ICD-9: 272.7] | Approved | [1] | |
| Company |
Protalix biotherapeutics
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C24H44N6O9
|
|||
| Canonical SMILES |
C(CCNC(=O)CCC(=O)NCCOCCNC(=O)CCC(=O)NCCCCC(C(=O)O)N)CC(C(=O)O)N
|
|||
| InChI |
1S/C24H44N6O9/c25-17(23(35)36)5-1-3-11-27-19(31)7-9-21(33)29-13-15-39-16-14-30-22(34)10-8-20(32)28-12-4-2-6-18(26)24(37)38/h17-18H,1-16,25-26H2,(H,27,31)(H,28,32)(H,29,33)(H,30,34)(H,35,36)(H,37,38)/t17-,18-/m0/s1
|
|||
| InChIKey |
CQPWQUAJPPFCDP-ROUUACIJSA-N
|
|||
| CAS Number |
CAS 1644392-61-9
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Alpha-galactosidase A (GLA) | Target Info | Modulator | [2] |
| KEGG Pathway | Galactose metabolism | |||
| Glycerolipid metabolism | ||||
| Sphingolipid metabolism | ||||
| Glycosphingolipid biosynthesis - globo series | ||||
| Lysosome | ||||
| Pathwhiz Pathway | Sphingolipid Metabolism | |||
| Galactose Metabolism | ||||
| Reactome | Glycosphingolipid metabolism | |||
| WikiPathways | Sphingolipid metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761161. | |||
| REF 2 | Characterization of a chemically modified plant cell culture expressed human alpha-Galactosidase-A enzyme for treatment of Fabry disease. Mol Genet Metab. 2015 Feb;114(2):259-67. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.